Sangamo Therapeutics (SGMO) News Today $0.50 +0.03 (+6.06%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SGMO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Sangamo Therapeutics (NASDAQ:SGMO) Given New $5.00 Price Target at BarclaysMay 16 at 2:47 AM | americanbankingnews.comStock Traders Buy High Volume of Sangamo Therapeutics Call Options (NASDAQ:SGMO)Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) was the recipient of unusually large options trading on Tuesday. Investors purchased 4,583 call options on the stock. This represents an increase of 61% compared to the average volume of 2,839 call options.May 15, 2025 | marketbeat.comSangamo Therapeutics Target of Unusually Large Options Trading (NASDAQ:SGMO)May 15, 2025 | americanbankingnews.comSangamo Therapeutics (NASDAQ:SGMO) Posts Earnings ResultsSangamo Therapeutics (NASDAQ:SGMO - Get Free Report) posted its earnings results on Monday. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.02). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%.May 14, 2025 | marketbeat.comSangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comSangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same DayMay 12, 2025 | finance.yahoo.comSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial ResultsMay 12, 2025 | businesswire.comSangamo Therapeutics Announces Pricing of $23.0 Million Underwritten OfferingMay 12, 2025 | businesswire.comSangamo Therapeutics Q1 2025 Earnings PreviewMay 12, 2025 | msn.comSchonfeld Strategic Advisors LLC Purchases Shares of 1,709,615 Sangamo Therapeutics, Inc. (NASDAQ:SGMO)Schonfeld Strategic Advisors LLC acquired a new position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 1,709,615 shares of the biMay 8, 2025 | marketbeat.comMarshall Wace LLP Has $344,000 Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)Marshall Wace LLP decreased its holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 85.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 337,130 shares of the biopharmaceutical company's stock afterMay 7, 2025 | marketbeat.comSangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry DiseaseMay 7, 2025 | finance.yahoo.comSangamo Therapeutics Announces First Quarter 2025 Earnings CallMay 6, 2025 | businesswire.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six analysts that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and four have issued a buMay 6, 2025 | marketbeat.com740,000 Shares in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Acquired by Acuta Capital Partners LLCAcuta Capital Partners LLC purchased a new stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 740,000 shares of the biopharmaceutical company'sMay 4, 2025 | marketbeat.comBoothbay Fund Management LLC Takes Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)Boothbay Fund Management LLC bought a new stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 537,219 shares of the biopharmaceuticalMay 3, 2025 | marketbeat.comSangamo Therapeutics (SGMO) Expected to Announce Quarterly Earnings on ThursdaySangamo Therapeutics (NASDAQ:SGMO) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-sangamo-therapeutics-inc-stock/)May 3, 2025 | marketbeat.comSangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)April 28, 2025 | businesswire.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Sold by Renaissance Technologies LLCRenaissance Technologies LLC lessened its stake in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 36.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,084,877 shares of the biopharmaceutical company's stApril 26, 2025 | marketbeat.comWasatch Advisors LP Decreases Stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)Wasatch Advisors LP cut its stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 52.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,231,505 shares of the biopharmaceutical company's stApril 19, 2025 | marketbeat.comQ1 EPS Forecast for Sangamo Therapeutics Raised by AnalystSangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2025 earnings per share estimates for shares of Sangamo Therapeutics in a research report issued to clients and investors on Monday, April 7th. HC Wainwright analyst P. TrucchioApril 12, 2025 | marketbeat.comResearch Analysts Set Expectations for SGMO Q4 EarningsSangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Research analysts at HC Wainwright reduced their Q4 2025 earnings per share estimates for shares of Sangamo Therapeutics in a report released on Monday, April 7th. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical comApril 11, 2025 | marketbeat.comSangamo Therapeutics' (SGMO) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Monday.April 9, 2025 | marketbeat.comSangamo up 53% to 95c after announcing license pact with Eli LillyApril 4, 2025 | markets.businessinsider.comSangamo announces capsid license agreement with Eli LillyApril 3, 2025 | markets.businessinsider.comShares of Sangamo Therapeutics Rally on Licensing Deal With Eli LillyApril 3, 2025 | marketwatch.comSangamo Therapeutics Enters Capsid License Agreement With LillyApril 3, 2025 | marketwatch.comSangamo Therapeutics stock soars on Lilly licensing dealApril 3, 2025 | investing.comSangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous SystemApril 3, 2025 | finance.yahoo.comTruist Financial Sticks to Its Buy Rating for Sangamo Biosciences (SGMO)March 19, 2025 | markets.businessinsider.comSangamo Therapeutics (NASDAQ:SGMO) Receives Sector Perform Rating from Royal Bank of CanadaRoyal Bank of Canada reiterated a "sector perform" rating and set a $2.00 target price on shares of Sangamo Therapeutics in a research report on Tuesday.March 19, 2025 | marketbeat.com3SGMO : 8 Analysts Assess Sangamo Therapeutics: What You Need To KnowMarch 18, 2025 | benzinga.comSangamo Therapeutics (NASDAQ:SGMO) Announces Earnings Results, Misses Estimates By $0.02 EPSSangamo Therapeutics (NASDAQ:SGMO - Get Free Report) announced its earnings results on Monday. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%.March 18, 2025 | marketbeat.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2024 Earnings Call TranscriptMarch 18, 2025 | msn.comRBC Capital Sticks to Their Hold Rating for Sangamo Biosciences (SGMO)March 18, 2025 | markets.businessinsider.comSangamo Biosciences (SGMO) Gets a Hold from Wells FargoMarch 18, 2025 | markets.businessinsider.comSangamo Therapeutics shares fall as Q4 results miss estimatesMarch 18, 2025 | investing.comSangamo reports Q4 EPS (11c) vs (34c) last yearMarch 18, 2025 | markets.businessinsider.comSangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial ResultsMarch 18, 2025 | finance.yahoo.comSangamo options imply 29.8% move in share price post-earningsMarch 18, 2025 | markets.businessinsider.comSangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call TranscriptMarch 17, 2025 | seekingalpha.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Rating of "Moderate Buy" from BrokeragesSangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and four have issued a buy ratinMarch 16, 2025 | marketbeat.comSangamo Therapeutics (SGMO) Expected to Announce Earnings on MondaySangamo Therapeutics (NASDAQ:SGMO) will be releasing earnings before the market opens on Monday, March 17, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=673373)March 15, 2025 | marketbeat.comSangamo Therapeutics Target of Unusually High Options Trading (NASDAQ:SGMO)Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) saw some unusual options trading on Wednesday. Traders bought 23,134 call options on the company. This represents an increase of approximately 432% compared to the average volume of 4,347 call options.March 13, 2025 | marketbeat.comDianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue EstimatesMarch 11, 2025 | msn.comSangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor ConferenceMarch 6, 2025 | businesswire.comSangamo Therapeutics (SGMO) Projected to Post Earnings on WednesdaySangamo Therapeutics (NASDAQ:SGMO) will be releasing earnings before the market opens on Wednesday, March 12, Financial Modeling Prep reports.March 5, 2025 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO shareholders incur further losses as stock declines 15% this week, taking five-year losses to 89%March 1, 2025 | uk.finance.yahoo.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the six research firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendationFebruary 19, 2025 | marketbeat.comTD Cowen Sticks to Its Buy Rating for Sangamo Biosciences (SGMO)February 7, 2025 | markets.businessinsider.com Get Sangamo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter. Email Address SGMO Media Mentions By Week SGMO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SGMO News Sentiment▼0.240.62▲Average Medical News Sentiment SGMO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SGMO Articles This Week▼153▲SGMO Articles Average Week Get Sangamo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RGLS News ZBIO News MYGN News VSTM News RIGL News EBS News XOMA News LXRX News VNDA News CDXS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SGMO) was last updated on 5/19/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sangamo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
